Lutris Pharma to Present at the American Association for Cancer Research Annual Meeting 2025
New Clinical Data from Phase 2 Trial of LUT014 for the Treatment of Patients With EGFRI-Induced Acneiform Rash Accepted for Oral Presentation at the Clinical Trials Plenary Session
TEL AVIV, Israel, March 26, 2025 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose limiting toxicity, today announced the upcoming presentation of the results of its double-blind, placebo-controlled phase 2 randomized clinical trial of lead compound, LUT014 gel. The topically-applied novel B-Raf inhibitor is optimized for paradoxical MAPK activation, for patients treated with epidermal growth factor receptor (EGFR) inhibitor therapy who develop dose-limiting acneiform rash. The new clinical data will be released in an oral presentation at the Clinical Trials Plenary Session at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 25-30 in Chicago, IL.
Presentation Details:
Presentation Title: A double-blind placebo-controlled randomized phase 2 clinical trial to assess the efficacy of a topical BRAF inhibitor for acneiform rash toxicities from anti-EGFR therapies
Presenting Author: Anisha B. Patel, MD, Associate Professor, Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX
Abstract Number: CT018
Session Title: New Frontiers in Precision Oncology
Session Date: Sunday, April 27, 2025
Session Time: 3:30 pm – 5:30 pm CT
About EGFR Inhibitor-Induced RashEGFR is a receptor on the surface of cells which is expressed in many normal epithelial tissues, including skin. The EGFR signaling pathway is one of the key pathways that regulate growth, survival, proliferation, and differentiation of cells. B-Raf is a protein encoded by the BRAF gene and is a downstream effector component of the EGFR signaling pathway. EGFR has been shown to be over-activated in various human cancers, including colorectal, lung, head and neck, urinary bladder, pancreatic and breast cancers, eliciting downstream phosphorylation and activation of the MAP Kinase pathway.
EGFR inhibitors can block the EGFR signal responsible for cell growth. Among the various types of pharmacological therapies for cancer, EGFR inhibitors are increasingly being used both as primary therapy as well as in patients who have progressed on prior chemotherapy treatments. Although effective as anti-cancer therapy leading to tumor shrinkage, EGFR inhibitors have many adverse reactions associated with their use. The majority of patients treated with EGFR inhibitors will experience adverse dermatological side effects typically manifested as a papulopustular skin rash, also known as acneiform lesions, which can impact quality of life and affect adherence to therapy.
About LUT014LUT014 is a novel B-Raf inhibitor which is applied topically to the skin. When the B-Raf protein is mutated, as is the case in some human cancers such as melanoma, blocking this pathway leads to apoptosis of the cells and tumor shrinkage. However, when the same pathway is blocked in normal, non-mutated cells, the opposite happens: the MAPK pathway is activated, and cells start growing. This phenomenon is recognized as the paradoxical effect of B-Raf Inhibitors. LUT014 harnesses the paradoxical effect of B-Raf Inhibitors in order to enhance cell proliferation and balance cell destruction, typical to radiation dermatitis.
About Lutris PharmaLutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma's lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and has successfully completed a phase 1/2 study for the treatment of radiation-induced dermatitis in breast cancer patients.
For more information, please visit www.lutris-pharma.com.
Contacts:
Lutris PharmaNoa Shelach, Ph.D. Chief Executive Officerir@lutris-pharma.com
Rx Communications GroupMichael Miller+1-917-633-6086mmiller@rxir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/lutris-pharma-to-present-at-the-american-association-for-cancer-research-annual-meeting-2025-302411050.html
SOURCE Lutris Pharma
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Liberty Mutual Insurance Elects Gordon Watson to the Company's Board of Directors
BOSTON, June 12, 2025 /PRNewswire/ -- Liberty Mutual Insurance Chairman and Chief Executive Officer (CEO) Tim Sweeney today announced that Gordon Watson, formerly the Chair of AXA Asia and CEO of AXA Asia & Africa, has been elected to the company's board of directors. "We are pleased to welcome Gordon to our board of directors. His extensive background in the insurance industry and dedication to promoting holistic health and leadership development in the workplace will bring invaluable insights as we navigate the evolving market landscape," said Sweeney. "Gordon's global perspective and vast experience in the well-being space will help us continue creating value for our policyholders and partners and shape a winning culture." Watson has a distinguished career with over three decades of experience in the insurance sector. Previously, he served as the Chair of AXA Asia and CEO of AXA Asia & Africa, where he led operations across 18 countries and drove critical transformation efforts. Prior to this, he was the Regional Chief Executive of AIA where he played a key role in its post-IPO profitable growth across various countries and group functions, from employee benefits to Vitality. Watson has also held key global leadership positions at AIG Life Companies in Japan and Korea, as well as Alico (now MetLife), working in London, New York, Nairobi, Dubai, Tokyo, Seoul and Hong Kong. He previously served as a board member of LIMRA and as the non-Executive Chairman of Tricor Services Limited. Watson is also an advocate for mental health and serves on the board of OneMind, a US-based nonprofit organization focused on improving mental health. He co-led the development of the Mental Health at Work Index with Columbia University, allowing companies to effectively measure the impact of their mental health strategies. He is the founding chair of Shared Value Initiative, Hong Kong, where he collaborates with industry leaders to create economic value while addressing social and environmental challenges, as well as a co-founder of MiYA, a platform that integrates customer tech and data science to create better health outcomes. Watson is also a founding member of LIFTwomen, a platform supporting female entrepreneurs around the world; LiftART, which offers support to artists from emerging countries; and World Flourishing Organization, which aims to transform the global workforce and help employees thrive. He has master of business administration from the University of Hull and a master's degree in Global Mental Health from the University of Glasgow. Watson is also a Fellow of the Chartered Insurance Institute from Glasgow Caledonian University and is certified coach through the Berkeley Executive Coaching Institute. "I am honored to join the Liberty Mutual board of directors and work closely with the management team as we face the complexities of the insurance industry. I am committed to leveraging my experience to drive the organization's success now and in the future, and look forward to helping the company achieve its goals," said Watson. About Liberty Mutual Insurance At Liberty Mutual, we believe progress happens when people feel secure. By providing protection for the unexpected and delivering it with care, we help people embrace today and confidently pursue tomorrow. In business since 1912, and headquartered in Boston, today we are the ninth largest global property and casualty insurer based on 2024 gross written premium. We also rank 91 on the Fortune 100 list of largest corporations in the US based on 2024 revenue. As of December 31, 2024, we had $50.2 billion in annual consolidated revenue. We employ over 40,000 people in 28 countries and economies around the world. We offer a wide range of insurance products and services, including personal automobile, homeowners, specialty lines, reinsurance, commercial multiple-peril, workers compensation, commercial automobile, general liability, surety, and commercial property. For more information, visit Contact: Liberty Mutual Insurance Public & Media Relationsmediarelations@ View original content to download multimedia: SOURCE Liberty Mutual Insurance Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications
PITTSBURGH and TAIPEI, June 12, 2025 /PRNewswire/ - MolecuLight Corp., a global pioneer in point-of-care fluorescence imaging for wound care, and its Taiwanese distributor, Healtdeva Company Ltd., congratulate researchers at Shuang-Ho Hospital in Taipei, Taiwan on their publication of groundbreaking findings using MolecuLight. The clinical study demonstrates the transformative impact of MolecuLight's i:X® device on the management of deep sternal wound infections (DSWI), showcasing significantly improved patient outcomes alongside cost savings and reduced burden on the healthcare system. The pivotal study, titled "Effects of adjuvant hyperbaric oxygen therapy and real-time fluorescent imaging on deep sternal wound infection: a retrospective study," published in the Journal of Wound Care (2025), revealed that incorporating MolecuLight's real-time fluorescence imaging into the treatment protocol for DSWI led to faster infection resolution, a dramatic reduction in antibiotic use and associated costs, shorter and less intensive hospital stays, and significantly lower rates of dangerous complications like reinfection and osteomyelitis compared to the standard of care with hyperbaric oxygen therapy (HBOT). Key findings that underscore the power of MolecuLight imaging: Significantly Improved Infection Control: MolecuLight-guided treatment increased the likelihood of white blood cell counts returning to normal within 7 days by 26-fold (72.7% vs. 9.1%) and C-reactive protein levels normalizing within 14 days by 7-fold (78.8% vs. 31.8%) compared to HBOT. Reduced Antibiotic Use and Costs: The MolecuLight group required antibiotics for a significantly shorter duration (22 days vs. 29.5 days), leading to nearly two-thirds lower antibiotic costs ($573.57 USD vs. $1643.78 USD). Faster Healing and Reduced Burden on Healthcare Systems: Patients treated with MolecuLight experienced ICU stays that were 70% shorter (3 days vs. 10 days) and achieved complete wound healing 20% faster (40 days vs. 50 days). Significantly Lower Risk of Complications: The use of MolecuLight imaging was associated with an 82% lower likelihood of in-hospital wound reinfection and an 86% lower risk of recurrent osteomyelitis, critical factors in long-term patient well-being and reduced healthcare expenditure. Enhanced Debridement Efficacy: The study highlights MolecuLight's ability to guide more precise and effective debridement, a cornerstone of successful wound management and infection control. "This study demonstrates that MolecuLight delivers tangible benefits in clinical wound management and also serves as a valuable teaching tool in our daily practice. The ability to visualize bacterial presence in real time allows us to more effectively guide younger physicians in understanding critical principles of infection control and intraoperative wound assessment. Moving forward, we intend to continue using this technology to enhance clinical decision-making and overall patient care," said study author Dr. Shun-Cheng Chang, from Shuang-Ho Hospital. "We are honored to introduce MolecuLight's advanced real-time fluorescence imaging technology to Taiwan," remarked Wei-Pin Hsieh, CEO of Healtdeva Company Ltd. "This innovation provides clinicians with a more efficient and accurate tool for assessing infections, opening new diagnostic perspectives in the management of complex wounds and post-operative care. We firmly believe that this technology will have a profound impact on improving patient outcomes and reducing overall healthcare costs." This study underscores the growing recognition of MolecuLight's significant utility beyond chronic wound care and its increasing adoption in critical surgical applications. The company's advanced imaging system, with its unique ability to visualize bacterial presence in real-time and guide targeted interventions, is gaining traction among surgeons looking to optimize outcomes and better manage post-operative complications in various surgical procedures, including the management of deep sternal wound infections (DSWI). "We wish to commend the researchers for their excellent work on this study," said Anil Amlani, CEO of MolecuLight. "These compelling results further validate the significant clinical and economic value of MolecuLight's technology, not only in chronic wound care but also in critical surgical applications. This study, along with our growing adoption in surgical settings, reflects the increasing recognition of our ability to provide critical, real-time information that empowers clinicians to make better decisions at the point of care, ultimately improving patient outcomes and reducing the burden of post-operative complications. We are proud to partner with Healtdeva Company to bring these benefits to patients in Taiwan." About MolecuLight Corp. is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications. About Healtdeva Company Company Ltd. was established in 1992 and is based in Taipei, Taiwan. Healtdeva Company Ltd. is a trusted distributor of medical technologies and healthcare solutions, with a well-established network across hospitals, clinics, and retail pharmaceuticals, advanced wound care, infection control, and preventive health. Healtdeva Company partners with global innovators to bring cutting-edge medical solutions to the Taiwanese market, driving clinical adoption and commercial success through localized expertise and strategic channel integration. View original content to download multimedia: SOURCE MolecuLight Corp.
Yahoo
an hour ago
- Yahoo
Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS) rate of 74.2% DZD8586 exhibited significant antitumor activity in heavily pretreated chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL) patients with an objective response rate (ORR) of 84.2% Both golidocitinib and DZD8586 will be featured in oral presentations at ICML 2025, with DZD8586 also presented in an oral session at ASCO 2025 SHANGHAI, June 12, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that it will present research findings on two of its first-in-class hematologic oncology assets—golidocitinib and DZD8586—at the 2025 European Hematology Association (EHA) Annual Congress and the 18th International Conference on Malignant Lymphoma (ICML). These include long-term follow-up data on golidocitinib as a maintenance therapy in peripheral T-cell lymphoma (PTCL) after first-line systemic therapy and pooled analysis results for DZD8586 in chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL/SLL), both selected for oral presentations at ICML. Golidocitinib Shows Potential to Significantly Improve Patient Outcomes in PTCL PTCL patients who achieved tumor response with first-line standard therapy will relapse. Approximately 40% of patients with complete response and 80% with partial response experienced disease progression within 2 years after initial tumor response, and the prognosis of these relapsed patients was very poor. The 24-month follow-up results from JACKPOT26, a prospective, multicenter Phase 2 clinical study of golidocitinib will be unveiled at EHA and featured as an oral presentation at ICML. The data suggest that golidocitinib showed promising efficacy in maintaining and enhancing tumor response with an acceptable and manageable safety profile in patients with PTCLs post first-line therapies. In Cohort 1 (patients with complete response), the 24-month disease-free survival (DFS) rate reached 74.2%, with consistent efficacy observed across different subtypes. In Cohort 2 (patients with partial response), the complete response rate (CRR) was 50.0%, the median duration of response (DoR) was 23.9 months, and the median progression-free survival (PFS) was 17.4 months, with the longest PFS reaching 35.9 months and the patient was still responding. "Golidocitinib, a next-generation oral and highly selective JAK1 inhibitor, addresses a critical unmet need for effective maintenance therapy following first-line treatment in PTCL," said Professor Jie Jin, lead principal investigator of the JACKPOT26 study at the First Affiliated Hospital of Zhejiang University School of Medicine. "Its unique mechanism of action not only delivers strong anti-tumor activity—allowing 50% of patients with partial remission (PR) to achieve complete remission (CR)—but also modulates the tumor immune microenvironment through its anti-inflammatory and immunomodulatory effects. These unique features help delay relapse and extend survival, positioning golidocitinib as a highly promising option for maintenance therapy in PTCL." In addition, golidocitinib has shown encouraging antitumor activities and favorable safety profiles in combination with CHOP in 1st line PTCL patients, as well as in rare T-cell lymphoma subtypes, including relapsed/refractory T-cell large granular lymphocytic leukemia (r/r T-LGLL) and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL). Further studies are warranted to validate the results. DZD8586 Overcomes Multi-Drug Resistance in CLL and other B-NHL A pooled analysis of two phase I/II studies of DZD8586 in CLL/SLL patients previously treated with covalent/non-covalent Bruton's Tyrosine Kinase (BTK) inhibitors and BTK degraders was presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and will be presented at EHA. Subgroup analyses will be presented as an oral presentation at ICML. In heavily pretreated CLL/SLL, DZD8586 achieved an ORR of 84.2%. Tumor response with a manageable safety profile was observed irrespective of prior covalent/non-covalent BTKi, BTK degrader, or BCL-2 inhibitor treatment, and in patients with classic BTK resistance mutations (C481X) as well as other BTK mutations, including kinase-dead mutations. No drug-related bleeding, atrial fibrillation, or major cardiac events observed. A Phase II study of DZD8586 monotherapy in relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) will also be presented at EHA and ICML. Clinical activities from small molecule targeted drugs such as BTK inhibitors have been less than desired for the treatment of DLBCL. Compensatory or redundant pathway activation could be one of the main escape mechanisms. DZD8586, a novel LYN/BTK dual inhibitor, is designed to overcome these limitations by blocking both BTK and LYN signaling pathways, and thus potentially improve therapeutic outcomes. At recommended phase 2 doses (RP2Ds) of 50 mg and 75 mg QD, DZD8586 monotherapy demonstrated promising anti-tumor activity in r/r DLBCL. The majority of patients showed target lesion shrinkage, with a CRR of 35.5%. Complete responders showed durable responses, with 81.8% of patients remaining in response and the median DoR was not reached. Notably, it showed efficacy in both GCB and non-GCB subtypes, supporting its broad therapeutic potential. Dr. Xiaolin Zhang, CEO of Dizal, remarked, "We are excited that golidocitinib and DZD8586 have demonstrated promising potential in PTCL and B-cell non-Hodgkin lymphoma (B-NHL), two areas with substantial unmet clinical needs. The selection of multiple studies for oral presentations at global leading conferences represents a strong recognition of our capabilities in research and development and further affirms our commitment to bringing transformative therapies to patients worldwide." About golidocitinib (DZD4205)Golidocitinib is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. In June 2024, golidocitinib was approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (r/r PTCL). At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. All subtypes benefited well, and the ORR of common subtypes exceeded 40%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, the median duration of response (mDoR) reached 20.7 months. As of February 2024, golidocitinib showed a median overall survival (mOS) of 24.3 months. Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) were published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) were published in The Lancet Oncology (Impact Factor: 54.4). About DZD8586DZD8586 is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed as a potential treatment option for B-cell non-Hodgkin lymphoma (B-NHL). While Bruton's Tyrosine Kinase (BTK) inhibitors have been approved for the treatment of B-NHL, resistance can arise through two major mechanisms: the BTK C481X mutation and BTK-independent BCR signaling pathway activation. Currently, there is no targeted therapy available to address both resistance mechanisms, posing an urgent clinical challenge. Although BTK degraders have shown encouraging efficacy in early clinical studies, mutation-related resistance has been reported, and degrader-related toxicities may affect long-term clinical application. DZD8586 has high selectivity against other TEC family kinases (TEC, ITK, TXK and BMX). By targeting BTK and LYN, it blocks both BTK-dependent and -independent BCR-signaling pathways, effectively inhibiting tumor growth of B-NHLs in cell lines and in animal models. Phase I clinical trial suggests that DZD8586 exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL. About DizalDizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deeply rooted in translational science and molecular design, it has established an internationally competitive portfolio with two leading assets in global pivotal studies, both of which have already been launched in China. To learn more about Dizal, please visit or follow us on Linkedin or X. Forward-Looking StatementsThis news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", and "intend" and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal's competitive environment, and political, economic, legal, and social conditions. Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect. ContactsInvestor Relations: ir@ Development: bd@ Contact: pr@ View original content to download multimedia: SOURCE Dizal Pharmaceutical Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data